Table 2 Reaction rates associated with allergic reactions after dosing by organ system, grade, and time period of LTFU study
From: Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab
Reaction numbers and % of total reactions | Reaction numbers for ITT | Month 0–6 | Month 7–19 | Month 20–32 | Month 33–62 |
|---|---|---|---|---|---|
Number of participants | 34 | 34 | 34 | 32 | |
Total ITT reactions | 1126 | 671 | 342 | 99 | 14 |
Gastrointestinal | 71 (6.3%) | 47 (7%) | 22 (6.4%) | 2 (2%) | 0 (0%) |
Mild | 71 | 47 | 22 | 2 | 0 |
Moderate | 0 | 0 | 0 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 |
Respiratory/thoracic/mediastinal | 55 (4.9%) | 39 (5.8%) | 16 (4.7%) | 0 (0%) | 0 (0%) |
Mild | 52 | 37 | 15 | 0 | 0 |
Moderate | 3 | 2 | 1 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 |
Skin/subcutaneous | 569 (50.5%) | 302 (45%) | 202 (59.1%) | 61 (61.6%) | 4 (28.6) |
Mild | 530 | 270 | 196 | 60 | 4 |
Moderate | 35 | 30 | 4 | 1 | 0 |
Severe | 4 | 2 | 2 | 0 | 0 |
Eye | 25 (2.2%) | 21 (3.1%) | 2 (0.6%) | 2 (2%) | 0 (0%) |
Mild | 25 | 21 | 2 | 2 | 0 |
Moderate | 0 | 0 | 0 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 |
Cardiovascular | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Nasal congestion | 227 (20.2%) | 128 (19.1%) | 71 (20.8%) | 21 (21.2%) | 7 (50%) |
Mild | 219 | 120 | 71 | 21 | 7 |
Moderate | 7 | 7 | 0 | 0 | 0 |
Severe | 1 | 1 | 0 | 0 | 0 |
Other (i.e. anxiety) | 179 (15.9%) | 134 (20%) | 29 (8.5%) | 13 (13.1%) | 3 (21.4%) |
Mild | 179 | 134 | 29 | 13 | 3 |
Moderate | 0 | 0 | 0 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 |